Segment Data

9 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Segment Data

Segment Data

The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

Revenues by segment, organizational unit and geographical areas for the three and nine-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended June 30,
(Millions of dollars)	2021						2020
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	560	$	447	$	1,007	$	412	$	369	$	781
Medication Management Solutions	459		139		597		500		177		677
Diabetes Care	152		143		294		136		123		260
Pharmaceutical Systems	112		364		476		113		291		403
Total segment revenues	$	1,283	$	1,092	$	2,375	$	1,161	$	960	$	2,122
Life Sciences
Integrated Diagnostic Solutions	$	435	$	682	$	1,117	$	344	$	370	$	714
Biosciences	124		192		316		93		145		237
Total segment revenues	$	559	$	874	$	1,433	$	436	$	515	$	951
Interventional
Surgery	$	267	$	69	$	336	$	154	$	43	$	197
Peripheral Intervention	238		198		436		174		143		318
Urology and Critical Care	227		83		310		194		74		268
Total segment revenues	$	732	$	350	$	1,082	$	522	$	260	$	782
Total Company revenues	$	2,574	$	2,316	$	4,890	$	2,119	$	1,735	$	3,855

	Nine Months Ended June 30,
(Millions of dollars)	2021						2020
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	1,659	$	1,355	$	3,014	$	1,450	$	1,183	$	2,634
Medication Management Solutions	1,376		417		1,793		1,412		408		1,820
Diabetes Care	450		414		863		417		389		806
Pharmaceutical Systems	292		985		1,277		287		815		1,102
Total segment revenues	$	3,777	$	3,170	$	6,947	$	3,566	$	2,797	$	6,362
Life Sciences
Integrated Diagnostic Solutions	$	1,904	$	2,141	$	4,045	$	1,143	$	1,204	$	2,347
Biosciences	365		588		953		353		487		840
Total segment revenues	$	2,269	$	2,729	$	4,998	$	1,496	$	1,691	$	3,187
Interventional
Surgery	$	757	$	203	$	960	$	659	$	176	$	835
Peripheral Intervention	692		590		1,282		641		471		1,112
Urology and Critical Care	672		255		926		603		235		837
Total segment revenues	$	2,120	$	1,047	$	3,168	$	1,903	$	881	$	2,784
Total Company revenues	$	8,166	$	6,947	$	15,113	$	6,964	$	5,369	$	12,333

Segment income for the three and nine-month periods was as follows:

	Three Months Ended June 30,				Nine Months Ended June 30,
(Millions of dollars)	2021		2020		2021		2020
Income Before Income Taxes
Medical (a)	$	636	$	646	$	1,936	$	1,653
Life Sciences (b)	432		214		1,953		860
Interventional	214		100		725		556
Total Segment Operating Income	1,282		960		4,613		3,069
Acquisitions and other restructurings	(24)		(74)		(126)		(235)
Other operating income (expense), net (c)	72		15		(224)		15
Net interest expense	(113)		(133)		(351)		(400)
Other unallocated items (d)	(703)		(520)		(1,937)		(1,608)
Total Income Before Income Taxes	$	514	$	248	$	1,976	$	842

(a)The amount for the nine months ended June 30, 2021 includes charges of $37 million, and the amounts for the three and nine months ended June 30, 2020 include an adjustment and charges of $(18) million and $240 million, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for AlarisTM infusion pumps in the Medication Management Solutions unit. Additionally, amounts for the three and nine months ended June 30, 2020 included costs related to another product matter of $8 million which were recorded in Other (expense) income, net.

(b)The amount for the nine-month period ended June 30, 2020 included a charge of $39 million recorded to Cost of products sold to write down the carrying value of certain intangible assets in the Biosciences unit.

(c)The amounts for the three and nine-months ended June 30, 2021 include a gain on a sale-leaseback transaction of $88 million, which is further discussed in Note 14, and $16 million of costs incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business. The amount for the nine-month period in 2021 also includes pre-tax charges of $296 million related to certain product liability matters, which is further discussed in Note 5.

(d)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.